Issue 49: Nanomedicine business and product news October-November 2017


Nanomedicine company announces clinical trial for nanoparticle cancer therapy NanOlogy LLC, a clinical-stage pharmaceutical development company, has announced enrollment of the first patient in a Phase 2 clinical trial of intraperitoneally (IP) administered NanoPac®(nanoparticle paclitaxel) sterile suspension in patients with ovarian cancer. Part of a broad nanoparticle technology platformdeveloped by the company, NanoPac will be


You need to be a subscriber to Nanotech Magazine to view this page. If you are a member please log-in, if you are not and wish to view this content please go to